| **Parameter** | **Rnd** | **NTCC Phase II119, 127** | **HPV FOCAL125, 128-130**‡ | **FINNISH124** | **NTCC Phase I119, 131, 132** | **SWEDESCREEN118, 135** | **ARTISTIC116, 136-138** | **POBASCAM120, 133, 134** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ages recruited | -- | 25-60 years | 25-65 years | 25-65 years | 25-60 years | 32-38 years | 20-64 years | 29-61 years |
| Definition of screened negative | 1 | IG: hrHPV-  CG: ASC-US- | IG: hrHPV-  CG: ASC-US- | IG: hrHPV-  CG: ASC-US- | IG: hrHPV-/ASC-US-  CG: ASC-US- | IG: hrHPV-/ASC-US-  CG: ASC-US- | IG: hrHPV-/ASC-US-  CG: ASC-US- | IG: hrHPV-/BMD-  CG: BMD- |
| 2 | IG: ASC-US-  CG: ASC-US- | -- | -- | IG: ASC-US-  CG: ASC-US- | IG: ASC-US-  CG: ASC-US- | IG: hrHPV-/ASC-US-  CG: ASC-US- | IG: hrHPV-/BMD-  CG: hrHPV-/BMD- |
| Followup (years) | 1 | 3.5 years (maximum) | 2-4 years (maximum)§ | 5 years (maximum) | 3.5 years (maximum) | 3 years (maximum) | 2.2 years (maximum) | 4 years (maximum) |
| 2 | 3.5 years (maximum) | 2 years (maximum) | -- | 3.5 years (maximum) | NR | 2.3 years (maximum) | 5 years (maximum) |
| Number of screened negative women with ICC | 1 | IG: 0/22,725 (0%)  CG: 0/23,710 (0%) | NR | IG: 5/57,135 (0.01%)  CG: 2/61,241 (0.003%) | IG: 0/20,687 (0%)  CG: 0/21,611 (0%) | NR | IG: 0/14,367 (0%)  CG: 0/5,338 (0%) | IG: 0/18,593 (0%)  CG: 1/19,400 (0.005%) |
| 2 | NR | -- | -- | NR | NR | IG: 0/9,334 (0%)\*  CG: 0/3,656 (0.0%)\* | IG: 0/8,962 (0%)  CG: 0/8,838 (0%) |
| Number of women diagnosed with ICC that had been screened negative | 1 | NR | NR | IG: 5/17 (29.4%)  CG: 2/9 (22.2%) | IG: 0/ NR (0%)║  CG: 0/ NR (0%)║ | NR | IG: 0/5 (0%)  CG: 0/4 (0%) | IG: 0/12 (0%)  CG: 1/6 (16.7%) |
| 2 | NR | -- | -- | NR | NR | IG: 0/3 (0%)\*  CG: 0/0 (0%)\* | IG: 0/4 (0%)  CG: 0/14 (0%) |

\*Preliminary or incomplete results

†In the control group, this is the second round of screening 4 years after enrollment; the first round of screening occurred 2 years after enrollment identified 17/6,447 [0.3%] women with CIN3+

‡From author inquiry

§HPV FOCAL had two randomized hrHPV arms: safety arm (screening every 2 years) and intervention arm (screening every 4 years); control arm screened every 2 years

║The total number of ICC was NR, but it is reported that there were zero cases of ICC in screened negative women.

**Abbreviations**: ASC-US = atypical cells of undetermined significance; BMD = borderline or mild dyskaryotic; CG = control group; CIN = cervical intraepithelial neoplasia; hrHPV = high risk human papillomavirus; ICC = invasive cervical cancer; IG = intervention group; NR = not reported